New Mexico Patent of the Month – May 2024
The quest for effective RNA-based therapeutics and diagnostics has led to groundbreaking innovations in nucleotide synthesis. Among these innovations, Nature’s Toolbox, Inc. (NTx) emerges with a revolutionary system for the production of pseudouridine compounds, a critical component in stabilizing RNA molecules.
At the heart of NTx’s invention lies a meticulously designed system comprising isolated uracil nucleobase and ribose-5-phosphate. These substrates undergo a series of enzymatic and chemical transformations orchestrated to produce pseudouridine-5′-monophosphate (ΨMP), the cornerstone of NTx’s method.
Central to the process is pseudouridine-5′-phosphate glycosidase (PsuG), an enzyme catalyst that facilitates the conversion of uracil nucleobase and ribose-5-phosphate into ΨMP. PsuG, derived from either thermophilic or enteric bacteria, catalyzes this transformation with remarkable efficiency, laying the foundation for subsequent steps.
Following PsuG’s enzymatic action, a protecting agent, often hexamethyldisilazane (HMDS), reacts with ΨMP, forming a protected ΨMP. This protective step ensures the stability of the compound throughout the synthesis process, safeguarding against undesired reactions.
Next, a methylating agent, typically iodomethane, reacts with the protected ΨMP, yielding a protected N1-methyl-pseudouridine-5′-monophosphate (protected m1ΨMP) compound. This methylation step introduces critical modifications essential for the desired properties of the final product.
Subsequently, a deprotection agent, commonly consisting of a combination of ammonia and methanol, removes the protecting groups, resulting in the formation of N1-methyl-pseudouridine-5′-monophosphate (m1ΨMP). This deprotection step unveils the active form of the compound, poised for further modification.
Finally, a phosphorylating agent, often polyphosphate kinase (PPK2) sourced from thermophilic bacteria like Deinococcus geothermalis, catalyzes the sequential phosphorylation of m1ΨMP, culminating in the production of N1-methyl-pseudouridine-5′-diphosphate (m1ΨDP) and N1-methyl-pseudouridine-5′-triphosphate (m1ΨTP). This phosphorylation process imparts crucial functionalization, rendering the final product ready for therapeutic applications.
NTx’s innovative system revolutionizes the production of pseudouridine compounds, addressing critical bottlenecks in RNA-based therapeutics and diagnostics. By combining enzymatic and chemical methodologies with precise substrate manipulation, NTx paves the way for a new era of RNA-focused innovations, promising transformative advancements in healthcare and beyond.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
